老年患者机器人辅助与开放根治性膀胱切除术围手术期并发症比较及衰弱的作用
该研究基于SEER-Medicare数据库纳入1750例66-89岁膀胱尿路上皮癌患者,采用倾向性评分加权模拟临床试验比较机器人辅助(RARC)与开放(ORC)根治性膀胱切除术。结果显示两组在围手术期输血、90天急诊就诊、再入院、并发症及肿瘤学结局上均无统计学显著差异,且基线衰弱水平未改变此关联。
要点
- RARC与ORC在老年患者围手术期并发症和肿瘤学结局上无显著差异。
- 基线衰弱水平未显著改变RARC与ORC的相对效果。
- 该观察性分析模拟iROC试验,未显示RARC优于ORC。
核心结论
- 在模拟iROC试验的观察性分析中,RARC与ORC相比未改善老年患者的围手术期并发症或肿瘤学结局,且与基线衰弱水平无关。
研究设计与样本
- 研究纳入2008至2017年SEER-Medicare数据库中66-89岁、Tis-T4/N0-N1/M0膀胱尿路上皮癌且接受根治性膀胱切除术的成人,共1750例(RARC 229例,ORC 1521例)。
- 采用稳定逆概率治疗加权(sIPW)平衡混杂因素,并通过交互项检验基线衰弱(基于索赔的衰弱指数CFI)的效应修饰作用。
主要发现
- 调整后,RARC与ORC在围手术期输血、90天急诊就诊、再入院及并发症发生率上均无统计学显著差异。
- 两组在癌症特异性死亡率和全因死亡率上亦无统计学显著差异。
- 在不同基线衰弱水平下,围手术期并发症和肿瘤学结局均无统计学显著差异。
临床怎么用
- 对于老年膀胱尿路上皮癌患者,选择RARC或ORC时,围手术期并发症和肿瘤学结局可能相似,决策需综合考虑其他因素。
- 基线衰弱水平可能不改变RARC与ORC的相对效果,但需个体化评估患者整体状况。
局限性
- 本研究为观察性分析,即使采用sIPW也可能存在残余混杂。
- 研究仅纳入SEER-Medicare数据库中66-89岁患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine the role of frailty as a potential effect modifier of the comparative effectiveness of robotic-assisted radical cystectomy (RARC) and open radical cystectomy (ORC) in older adults. Radical cystectomy (RC) is associated with high rates of perioperative morbidity, and frailty may serve as a potentially strong modifier of both perioperative and oncologic outcomes. We therefore emulated a pragmatic clinical trial of RARC versus ORC to examine this question. METHODS: We identified adults 66-89 years with Tis-T4 / N0-N1 / M0 urothelial carcinoma of bladder from 2008 to 2017 treated with RC in SEER-Medicare. Baseline frailty was assessed using the claims-based frailty index (CFI). Associations of RARC and ORC with perioperative and oncologic outcomes were examined in the overall cohort after stabilized inverse probability of treatment re-weighting (sIPW). Baseline frailty was examined as an effect modifier using interaction terms in separate models. RESULTS: A total of 1,750 patients were included in the study cohort, of whom 229 underwent RARC and 1521 underwent ORC. Adjusted rates of perioperative blood transfusion or 90-day ER utilization, hospital readmission, and complications were not statistically significantly different between RARC and ORC. Similarly, there were no statistically significant differences in cancer-specific or all-cause mortality. Notably, there were no statistically significant differences in perioperative morbidity or oncologic outcomes across baseline frailty level. CONCLUSIONS: In observational analyses designed to emulate the iROC trial, RARC was not associated with improved perioperative morbidity or oncologic outcomes in older adults, regardless of baseline frailty level.
引用
- Almohtasib J, Black J, Kaul S, et al. Perioperative Morbidity of Robotic-Assisted Radical Cystectomy Versus Open Radical Cystectomy in Older Adults and the Role of Frailty as an Effect Modifier. Urology. 2026. PMID: 42800544. doi:10.1016/j.urology.2026.09.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。